PALM BEACH GARDENS, Fla., Dec. 9, 2010 /PRNewswire/ -- The national media keeps ringing the alarm and posting new stories on the disturbing results of the NYU one-year research study on pediatric dosing instructions on liquid medication, which is reported in the Journal of the American Medical Association‘s December issue. The results are shocking. An intense review of 200 of the top children’s liquid medications, found inconsistencies across all the medications, with the vast majority having a problem.(1)
(Logo: http://photos.prnewswire.com/prnh/20101209/FL15170LOGO )
Researchers, under the direction of Dr. H. Shonna Yin, assistant professor of pediatrics at NYU School of Medicine, found that 25 percent of the over-the-counter liquid medications don’t contain a dosing device like a cup, dropper, or dosing spoon for administering medication. According to Dr. Yin, “We also found that 99 percent had markings on the dosing device and directions on the label that do not match up exactly.” Early in 2010, Cornell University reported the gross inadequacy of dosing with a household spoon that conclusively leads to overdosing and underdosing.(2) Yet 25 percent of children’s liquid medications don’t contain a dosing device, even after the FDA called for greater consistency in dosing in November 2009.
In 2007, AccuDial Pharmaceutical, the maker of Children’s AccuDial pediatric medications, recognized that children were not being accurately dosed. The widespread number of parents that were unintentionally overdosing and also underdosing their children, and arriving at all hours at hospital emergency rooms across the country, was reaching epidemic proportions.
AccuDial met the problem head-on and created a next-generation solution. The solution is the only patented rotating weight-based dosing system designed specifically to properly calculate and administer children’s pediatric liquid medications. AccuDial’s dosing label dials in a child’s weight in two-pound increments and shows the correct weight-based dose in milliliters (mL). The medicine is then administered with an accurately calibrated dosing spoon in mL and 1/2 mL that is included in every package. AccuDial provides parents with a foolproof method of minimizing dosing errors, with weight-specific dosing and a perfectly matched dosing spoon.
AccuDial is the industry leader in focusing on the critical issue of inaccurate dosing of over-the-counter medications for children. “Measuring dosages using a specific formula based on weight is standard practice among health care professionals such as doctors, nurses, and pharmacists. Children’s AccuDial is a game changer in the pharmaceutical industry with its line of eight children’s medications, with weight-specific dosing, available in more than 4,000 pharmacies and stores across Canada. AccuDial expects to have products available in U.S. pharmacies next year,” said Bob Terwilliger, CEO of AccuDial.
About AccuDial Pharmaceutical
AccuDial is positioned to change the way liquid medications will be dosed globally. It is the only brand with a patented rotating weight-based dosing system designed to administer over-the-counter medications safely and effectively. For more information, visit accuratedose.com or call 561.429.6886.
The information contained in this press release includes “forward-looking statements.” All statements other than statements of historical facts included in this press release, including the Company’s prospects, plans, financial position, and business strategy, may constitute forward-looking statements. These statements are based on the beliefs and assumptions of our management and on the information currently available to our management at the time of such statements. Forward-looking statements generally can be identified by the words “believes,” “projects,” “expects,” “anticipates,” “intends,” “plans,” “estimates,” or similar expressions that indicate future events and trends. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, the Company can give no assurance that these expectations will prove to be correct, and the Company’s actual results may differ significantly from the results discussed in these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as the result of new information, future events, or otherwise.
(1) NYU School of Medicine, Shone, Laura P; Yin, H Shonna; Wolf, Michael S. “Medicine safety among children and adolescents”. Academic Pediatrics. 2010; 10: 218
(2) Wansink, Brian and Court van Ittersum, 2009, “Spoons Systemically Bias Dosing of Liquid Medicine.”
SOURCE AccuDial Pharmaceutical